ImaginAb licenses CD8 ImmunoPET tracer to Leucid Bio
2023-04-18
引进/卖出免疫疗法
Preview
来源: Pharmaceutical Technology
Leucid Bio will use ImaginAb’s CD8 ImmunoPET tracer along with LEU011 in its basket study to treat solid tumours. Credit: National Cancer InstituteCancer Institute on Unsplash.
Preview
来源: Pharmaceutical Technology
Biotechnology company ImaginAb has entered into a new non-exclusive licence and supply agreement with Leucid Bio for CD8 ImmunoPET technology.
ImaginAb will be responsible for licensing and supplying the clinical doses of 89Zr crefmirlimab berdoxam, its investigational CD8 ImmunoPET tracer, to Leucid Bio.
Leucid Bio will use the CD8 ImmunoPET tracer along with LEU011 targeting NKG2DL, autologous CAR T-cells, in its basket study to treat solid tumours.
ImaginAb CEO Ian Wilson stated: “We are delighted that Leucid Bio will use our investigational CD8 ImmunoPET for the first time in conjunction with CAR-T therapies.
“This agreement with Leucid Bio is an opportunity for ImaginAb to continue expanding our partnerships, and showcases the increasing adoption of our CD8 ImmunoPET technology.”
CD8 ImmunoPET (89Zr crefmirlimab berdoxam) is an 89Zr-labeled mini body, designed to bind to CD8 receptors on human T cells for non-invasive, quantitative PET imaging.
The technique is currently being investigated for diagnosing the immune status of a patient, measuring the efficacy of immunotherapies and predicting patients’ outcomes.
Leucid Bio chief business officer Artin Moussavi said: “This is an exciting partnership for Leucid as this cutting-edge technology will provide evidence of the biodistribution of LEU011 CAR T-cells.
“This will be the first time this technology will be used in a solid tumour CAR-T clinical setting, allowing Leucid to generate data that demonstrate the tracking of LEU011 to tumour sites in the first phase of the trial.
“This data would validate in humans the significant improvements already demonstrated with LEU011 in preclinical studies.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。